News - North America, Depomed


Current filters:

North AmericaDepomed

Popular Filters

Mallinckrodt gains FDA approval for Xartemis XR

Mallinckrodt gains FDA approval for Xartemis XR


The US Food and Drug Administration has approved Ireland-headquartered specially drugmaker Mallinckrodt’s…

DepomedMallinckrodtNeurologicalNorth AmericaPharmaceuticalRegulationUSAXartemis XR

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal


PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

US FDA grants priority review for Mallinckrodt's pain relief drug


The US Food and Drug Administration has accepted and granted a priority review for the New Drug Application…

DepomedMallinckrodtNorth AmericaOxycodone and AcetaminophenPharmaceuticalRegulation

Briefs: Depomed drops Sefelsa after CRL: Sun Pharma stalking Meda?


US specialty drugmaker Depomed (Nasdaq: DEPO) says that Food and Drug Administration issued a complete…

DepomedMedaMergers & AcquisitionsMetabolicsNorth AmericaPharmaceuticalRegulationResearchSefelsaSun Pharmaceutical Industries

Views on US physician prescribing and payer reimbursement across multiple neuropathic pain populations


Expanded labeling for additional neuropathic pain (NP) populations and/or broader NP labeling (peripheral…

DepomedGraliseHorizantJanssenMarkets & MarketingNeurologicalNorth AmericaNucyntaPharmaceuticalXenoPort

FDA should not approve paroxetine or gabapentin for hot flashes, says Public Citizen


A drug approved to treat depression and other mental health disorders and another designed to prevent…

DepomedgabapentinHisamitsu PharmaNorth AmericaparoxetinePharmaceuticalRegulationWomen's Health

Depomed sues FDA over orphan status exclusivity for Gralise


US drugmaker Depomed (Nasdaq: DEPO) says it has filed an action in federal district court for the District…

DepomedGraliseLegalNeurologicalNorth AmericaPharmaceuticalRare diseases

Depomed to file NDA for Serada; with Valeant sues Watson over Glumetza


US drugmaker Depomed (Nasdaq: DEPO) says that it has completed a Type B pre-New Drug Application meeting…

DepomedDiabetesGenericsGlumetzaNorth AmericaPatentsPharmaceuticalRegulationResearchSeradaValeant PharmaceuticalsWatson PharmaceuticalsWomen's Health

Mylan debuts Lescol copy; Impax challenges Gralise patent


US generic drug major Mylan (Nasdaq: MYL) revealed last Friday that it has begun shipping its generic…

Cardio-vascularDepomedGenericsGraliseImpax LaboratoriesLescolMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPatentsRegulation

Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity


Surveyed US neurologists and managed care organization (MCO) pharmacy directors agree that reducing pain…

DepomedGraliseJohnson & JohnsonLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticaltapentadol

Depomed files patent infringement suits relating to Gralise


California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US…

ActavisDepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Santarus and Depomed expand US deal on Glumetza


US drugmakers Santarus (Nasdaq: SNTS) and Depomed (Nasdaq: DEPO) have entered into a new commercialization…

DepomedDiabetesGlumetzaLicensingNorth AmericaPharmaceuticalSantarus

Back to top